as 05-20-2024 4:00pm EST
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Founded: | 1901 | Country: | Israel |
Employees: | N/A | City: | TEL AVIV |
Market Cap: | 18.5B | IPO Year: | N/A |
Target Price: | $14.22 | AVG Volume (30 days): | 10.1M |
Analyst Decision: | Buy | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.44 | EPS Growth: | N/A |
52 Week Low/High: | $7.09 - $17.13 | Next Earning Date: | 05-08-2024 |
Revenue: | $16,004,000,000 | Revenue Growth: | 7.22% |
Revenue Growth (this year): | 1.39% | Revenue Growth (next year): | 2.73% |
TEVA Breaking Stock News: Dive into TEVA Ticker-Specific Updates for Smart Investing
GuruFocus.com
3 days ago
MT Newswires
3 days ago
MT Newswires
5 days ago
Business Wire
5 days ago
Zacks
6 days ago
The Wall Street Journal
6 days ago
MT Newswires
7 days ago
Zacks
7 days ago